Application of serum tRFs as HBV (Hepatitis B Virus) related liver injury diagnostic marker

By using high-throughput tRF sequencing and qRT-PCR validation technology, tRF-Val-TAC, tRF-Lys-CTT, and tRF-Lys-TTT were identified as diagnostic biomarkers for HBV-ACLF, solving the problem of early diagnosis of hepatitis B virus-related liver failure and enabling early and accurate diagnosis and triage of hepatitis B-related diseases.

CN121975931APending Publication Date: 2026-05-05SUN YAT SEN UNIV +1
4 Cites 0 Cited by

Patent Information

Application Number
CN202512009198.0
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2025-12-29
Publication Date
2026-05-05

AI Technical Summary

Technical Problem

In the current technology, there is a lack of specific biomarkers for the early diagnosis of hepatitis B virus-associated acute-on-chronic liver failure (HBV-ACLF), which leads to patients being diagnosed only when the disease has progressed to a later stage, and traditional detection indicators are not sensitive enough.

Method used

Using high-throughput tRF sequencing combined with qRT-PCR validation, three tRFs—tRF-Val-TAC, tRF-Lys-CTT, and tRF-Lys-TTT—were identified as diagnostic biomarkers for HBV-related liver injury. Quantitative detection of the expression levels of these biomarkers provides support for early diagnosis.

Benefits of technology

It enables early and accurate diagnosis of hepatitis B-related acute-on-chronic liver failure, chronic hepatitis B, and cirrhosis, improving diagnostic sensitivity and specificity and providing a basis for personalized treatment plans.

✦ Generated by Eureka AI based on patent content.
Patent Text Reader

Abstract

The invention relates to the technical field of biological molecular diagnosis of hepatitis B related diseases, and particularly discloses a group of HBV related liver injury diagnostic markers and application thereof. According to the serum exosomes tRF-Val-TAC, tRF-Lys-CTT and tRF-Lys-TTT provided by the invention, the tRFs marker is tRFs combined detection of any one or combination of the sequences, and has the index advantages of high AUC value, high sensitivity and strong specificity; the method can solve the problem of difficulty in early and accurate diagnosis of hepatitis B-related chronic plus acute liver failure (HBV-ACLF) caused by pure dependence on traditional biochemical and blood coagulation indexes, and can meet various diagnosis requirements of ACLF, chronic hepatitis B and cirrhosis.
Need to check novelty before this filing date? Find Prior Art